Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
Microsoft’s Clippy-like Mico character is no longer the face of Copilot
- 10 hours ago
India's Padikkal hits unbeaten century in first Sri Lanka Test
- 18 hours ago
Banned outfit linked to targeted killing of three Lahore cops
- 20 hours ago
'No meeting with PTI founder': KP CM rejects Rs6.4bn federal deduction
- 17 hours ago
The fight over Flock and other ALPRs
- 10 hours ago
Iran calls for release of pilots captured in Qatar during Middle East war
- 19 hours ago
The Iran war’s mental toll on US sailors
- a day ago
Probe into alleged abuse at Lahore's Ghaziabad PS reveals cop's new connection with beggars
- 16 hours ago
Disney reveals Marvel's new 'X-Men' cast, 'Frozen 3' at D23 fan event
- a day ago
2K launches new studio to build its ‘next blockbuster sports franchise’
- 43 minutes ago
PSDF, SDA partner to boost skills and jobs for hearing-impaired youth
- 17 hours ago
Honor’s Robot Phone is better than a gimbal in a phone has any right to be
- 43 minutes ago
.jpg&w=3840&q=75)
